NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) and certain officers.  The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both date ...

NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross ProceedsJuly 25, 2025 3:04 PM EDT | Source: Phio Pharmaceuticals Corp.King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into definitive agreements to exercise certain outsta ...

Gilead stock is flashing "buy" in bright green letters.Biopharmaceuticals stock Gilead Sciences (GILD 2.70%) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded the shares to a buy rating and slapped a $133 price target on the $116 stock.Key to the analyst's analysis is Gilead's new Yeztugo prescription medication for pre-exposure prevention of HIV-1. What Needham says about GileadCiting a survey of physicians, Needham reports in a note covered on The Fly this morning that the market for ...

Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I put Cytokinetics, Incorporated (NASDAQ: CYTK ) in the spotlight for the first time in 2025. I last posted research on this mid-cap biopharma in November 2024. The stock hit a bump when a snag occurred around the approval ...

Key Takeaways New coverage sparks focus on KALA, GHM, ARQ, and HWKN amid economic and earnings uncertainty.KALA shares jumped 96.1% in 3 months; the 2025 loss per share estimate narrowed over the past 30 days.GHM gained 75.2% in 3 months with a rising EPS estimate; ARQ and HWKN also outperformed peers recently.In the current backdrop of heightened economic uncertainty—marked by tariff volatility, inflationary pressure, and growing concerns over policy interference—new analyst coverage plays a crucial role i ...

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth CohortJuly 25, 2025 12:36 PM EDT | Source: Phio Pharmaceuticals Corp.Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patientKing of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary I ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 25th:Revolve Group, Inc. (RVLV) : This online fashion retailer has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.9% over the last 60 days.Revolve’s shares gained 4.8% over the past month compared with the S&P 500’s advance of 3.7%. The company possesses a Momentum Score  of A.Pharming Group N.V. (PHAR) : This biopharmaceutical company has a Zac ...

【大河财立方 记者 王宁宁】7月24日，中国证监会召开证监会系统党的建设暨2025年年中工作会议。会议强调，要从资产端、资金端进一步固本培元，大力 推动上市公司提升投资价值，抓好"并购六条"和重大资产重组管理办法落实落地。 在政策工具箱持续丰富的过程中，A股并购市场重组事件明显增多，且呈现出"产业为先"的新趋势。7月25日，电磁屏蔽材料制造企业隆扬电子在回复深交 所重组问询函公告中称，通过收购德佑新材100%股权，在电子材料领域形成深度互补，将完善上市公司电子功能材料全产业链布局，推动复合型电子材料 开发及复合铜箔在高端场景应用。 从长三角的集成电路产业整合，到粤港澳大湾区的生物医药集群重构；从东海之滨的高端装备制造协同，到中原经济区的产业链体系升级，一场以市场化重 组推动产业升级的深刻变革正在全国铺开，重组典型案例相继涌现。 立足上海重点产业发展规划，2024年发布的《上海市支持上市公司并购重组行动方案（2025—2027年）》明确提到，聚焦新质生产力强链补链，在集成电 路、生物医药、人工智能等重点领域梳理链主企业；推动传统行业转型升级，开展同行业、上下游并购和吸收合并，合理提升产业集中度。 并购重组是支持 ...

Strategic Internal Review initiated for treasury diversification through a prospective digital asset subsidiary — no entity formed, no capital committedLA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated di ...